Warning Letter — Keta Med Lab / www.ketamedlab.com
The FDA issued a warning letter to Keta Med Lab for distributing unapproved and misbranded drug products via their website. The Center for Drug Evaluation and Research notified the firm of significant violations regarding the marketing of drugs without required FDA approvals.
This affects Keta Med Lab, its management, and digital operations teams. It also impacts online drug distributors and manufacturers involved in the e-commerce sale of pharmaceutical products without established regulatory clearance.
This enforcement action indicates CDER's ongoing surveillance of online platforms bypassing the New Drug Application (NDA) process. The issuance of a warning letter suggests that the FDA has identified public health risks related to the sale of unvetted substances. For regulatory professionals, this underscores the necessity of ensuring all digital marketing and product catalogs align strictly with FDA-approved labeling and registration requirements to avoid enforcement for misbranding or the sale of unapproved new drugs.
Firms should conduct immediate audits of website content and product claims to ensure no unapproved drug products are being marketed. Regulatory and legal teams should verify that all pharmaceutical offerings have valid NDAs or ANDAs and comply with labeling requirements. Monitoring of digital storefronts is essential to prevent the dissemination of non-compliant therapeutic claims.
FDA Warning Letter issued to: Keta Med Lab / www.ketamedlab.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/keta-med-lab-wwwketamedlabcom-725154-06232026
Open in openFDA / FDA.gov